News and Press Releases
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
23 May 2024 -- Tokyo, Japan -- Eisai Co announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American...
Category: Clinical Trials, Drug Discovery
Posted: May 23, 2024
Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis
China flagged as significant contributor to growth, but poor investigator selection is causing trial failures 23 May 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has...
Category: Biotechnology, Clinical Trials
Posted: May 22, 2024
Swixx Biopharma Expands to Latin America Through a Strategic Acquisition and Combination with Biopas
With the addition of $220m in sales, over 300 employees and therapeutic coverage in Neurology, Oncology, Immunology, Gastroenterology, Rare Diseases and Specialty, acquisition extends and transforms Swixx BioPharma’s footprint The...
Category: Other, Pharmaceutical
Posted: May 22, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Myonex Closes Creapharm Acquisition Expanding Global Services
2 May 2024 -- Pennsylvania, US -- Myonex has completed the previously announced acquisition of Creapharm’s pharmaceutical services business. This transaction combines capabilities and flexibility to serve pharmaceutical and biotech...
Category: Biotechnology, Pharmaceutical
Posted: May 2, 2024
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study
NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024
Myonex Announces Acquisition of Safeway Compounding Pharmacy to Expand its Clinical Trial Services Across the US
9 April 2024 -- Horsham, US -- Myonex, a leading global clinical trial supply company, has completed the acquisition of SaveWay Compounding Pharmacy of Newark, US. The pharmacy will operate as...
Category: Clinical Trials
Posted: April 9, 2024
Nonacus launches test for comprehensive genomic profiling, integrated with bioinformatics and analysis software
2 April 2024 -- Birmingham, UK -- Genetic testing company, Nonacus, has launched GALEAS Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumours, allowing clinicians...
Category: Biotechnology
Posted: April 2, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham B32 1AF, United Kingdom
Bora Pharmaceuticals completes the acquisition of Upsher-Smith
Acquisition expands Bora’s North American footprint with first US manufacturing site 1 April 2024 -- Taipei, Taiwan -- Bora Pharmaceuticals today announced that it has completed the acquisition of Upsher-Smith Laboratories,...
Category: BioManufacturing
Posted: April 1, 2024
6F., No. 2, Aly. 36, Ln. 26, Ruiguang Rd., Neihu District, Taipei City, 114 Taiwan
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
27 March 2024 -- Princeton, US, and Frankfurt, Germany -- Indegene, a digital-first, life sciences commercialisation company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider...
Category: Pharmaceutical
Posted: March 27, 2024
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthenpipeline in cardiovascular disease
25 March, 2024 -- Bagsværd, Denmark, and Hannover, Germany -- Novo Nordisk and CardiorPharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to€1.025bn, including an upfront...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 26, 2024
Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...
Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team
6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...
Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer
First time GMP manufacturing of a therapeutic IgE antibody has been achieved at scale GMP material to be used in phase 1b study in platinum-resistant ovarian cancer (PROC) patients scheduled...
Category: BioManufacturing
Posted: March 5, 2024
